secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytosorbents Corp (CTSO)
CIK:        0001175151
Form:       8-K
Filed at:   2026-08-06T20:19:09+00:00
Accession:  0001104659-26-092039
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CytoSorbents Q2 2026 revenue flat at $9.6M; operating loss improves 27%
-----------------------------------------------------------------------

- Revenue $9.6M (unchanged YoY); gross margin 73% (up from 71% YoY).
- Operating loss improved 27% to $2.6M; net loss $4.4M ($0.07) vs net income $1.9M ($0.03) in Q2 2025 due to FX.
- Adjusted net loss improved 22% to $2.8M ($0.05); adjusted EBITDA loss improved 38% to $1.6M.
- Cash burn reduced to $0.4M (incl. $0.2M restructuring); workforce cut 23% since Sep 2025.
- Two FDA pre-submission meetings in Aug 2026 for DrugSorb-ATR (Brilinta and DOAC programs).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1175151/000110465926092039/0001104659-26-092039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1175151/000110465926092039/tm2622246d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-092039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer